Intracervical PGE₂ vs placebo
- Pharmacological and mechanical interventions for labour induction in outpatient settings 2017 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Intracervical PGE₂ showed no clear difference in neonatal intensive care unit admission compared with placebo (low certainty).
Vaginal misoprostol showed no clear difference in uterine hyperstimulation (with fetal heart rate changes) compared with placebo (low certainty).
Vaginal misoprostol showed no clear difference in caesarean section compared with placebo (low certainty).
Vaginal misoprostol showed no clear difference in serious neonatal morbidity or death compared with placebo (low certainty).
Vaginal misoprostol showed no clear difference in neonatal intensive care unit admission compared with placebo (low certainty).
Vaginal PGE₂ showed no clear difference in uterine hyperstimulation (fetal heart rate changes unclear) compared with placebo or expectant management (low certainty).
Vaginal PGE₂ showed no clear difference in caesarean section compared with placebo or expectant management (low certainty).
Vaginal PGE₂ showed no clear difference in neonatal intensive care unit admission compared with placebo or expectant management (low certainty).
Intracervical PGE₂ showed no clear difference in vaginal birth not achieved in 48 to 72 h compared with placebo (low certainty).
It is very uncertain whether antispasmodics changes pain duration (mean pain duration, assessed at 4 weeks) compared with placebo (very low certainty).
It is very uncertain whether antispasmodics changes pain improvement (clinician judged, assessed at 2 weeks) compared with placebo (very low certainty).
It is very uncertain whether antispasmodics changes pain frequency (episodes of pain in 4 weeks, assessed after 4 weeks) compared with placebo (very low certainty).